Triennial review of pharmaceuticals

Every three years the FOPH reviews all pharmaceuticals on the specialities list to check whether they still meet the requirements for inclusion.

Division of medicines

Pharmaceuticals are assigned to one of three groups based on the therapeutic group of the specialities list they belong to. Each group is reviewed every three years:

Group A

Gastroenterology (04)
Metabolism (07)
Antidotes (15)
Cation exchangers (16)
Gastroenterology, complementary medicine (54)
Metabolism, complementary medicine (57)

Group B

Nervous system (01)
Kidneys and water balance (05)
Blood (06)
Dermatology (10)
Odontostomatology (13)
Diagnostics (14)
Nervous system, complementary medicine (51)
Kidneys and water balance, complementary medicine (55)
Blood, complementary medicine (56)
Dermatology, complementary medicine (60)

Group C

Cardiovascular (02)
Pulmonary and respiratory (03)
Infectious diseases (08)
Gynaecology (09)
Ophthalmology (11)
Otorhinolaryngology (12)
Other pharmaceuticals, complementary medicine (20)
Cardiovascular, complementary medicine (52)
Pulmonary and respiratory, complementary medicine (53)
Infectious diseases, complementary medicine (58)
Gynaecology, complementary medicine (59)
Ophthalmology, complementary medicine (61)
Otorhinolaryngology, complementary medicine (62)

Review 2026

Review 2025

Lists of the originals, generics, co-marketing and biosimilars with price reductions as of 1 December 2025 or later, subject to possible changes (in German and French).

Lists of the originals, generics, co-marketing and biosimilars without price reductions as of 1 December 2025 or later, subject to possible changes (in German and French).

List of pharmaceuticals subject to appeal

The pharmaceuticals which were the object of appeals in the Federal Administrative Court are published in the List of pharmaceuticals subject to an appeal against a decision of the FOPH (see page Information related to the specialities list).

Previous reviews

Lists of the originals, generics, co-marketing and biosimilars with price reductions as of 1 December 2024 or later, subject to possible changes (in German and French).
Lists of pharmaceuticals with price reductions resulting from the review in 2024
XLSX567.69 kB31 October 2025
Lists of the originals, generics, co-marketing and biosimilars without price reductions as of 1 December 2024 or later, subject to possible changes (in German and French).
Lists of pharmaceuticals without price reductions resulting from the review in 2024
XLSX146.06 kB31 October 2025
Triennial review of listing requirements in 2024: Publication of the basis for assessment
PDF10.30 MB1 December 2025
Lists of the originals, generics, co-marketing and biosimilars with price reductions as of 1 December 2023 or later, subject to possible changes (in German and French).
Lists of pharmaceuticals with price reductions resulting from the review in 2023
XLSX247.26 kB25 October 2024
Lists of the originals, generics, co-marketing and biosimilars without price reductions as of 1 December 2023 or later, subject to possible changes (in German and French).
Lists of pharmaceuticals without price reductions resulting from the review in 2023
XLSX384.02 kB25 October 2024
Lists of the originals, generics, co-marketing and biosimilars with price reductions as of 1 December 2022 or later, subject to possible changes (German and French).
Lists of pharmaceuticals with price reductions resulting from the review in 2022
XLSX228.12 kB3 October 2025
Lists of the originals, generics, co-marketing and biosimilars without price reductions as of 1 December 2022 or later, subject to possible changes (German and French).
Lists of pharmaceuticals without price reductions resulting from the review in 2022
XLSX147.23 kB3 October 2025
Lists of the originals, generics, co-marketing and biosimilars with price reductions as of 1 December 2021 or later, subject to possible changes (German and French).
Lists of pharmaceuticals with price reductions resulting from the review in 2021
XLSX272.37 kB28 October 2022
Lists of the originals, generics, co-marketing and biosimilars without price reductions as of 1 December 2021 or later, subject to possible changes (German and French).
Lists of pharmaceuticals without price reductions resulting from the review in 2021
XLSX165.36 kB28 October 2022
Lists of the originals, generics, co-marketing and biosimilars with price reductions as of 1 December 2020 or later, subject to possible changes (German and French).
Lists of pharmaceuticals with price reductions resulting from the review in 2020
XLSX214.33 kB29 October 2021
Lists of the originals, generics, co-marketing and biosimilars without price reductions as of 1 December 2020 or later, subject to possible changes (German and French).
Lists of pharmaceuticals without price reductions resulting from the review in 2020
XLSX173.20 kB29 October 2021
Lists of the originals, generics, co-marketing and biosimilars with price reductions as of 1 December 2019 or later, subject to possible changes (German and French).
Lists of pharmaceuticals with price reductions resulting from the review in 2019
XLSX251.95 kB29 October 2020
Lists of the originals, generics, co-marketing and biosimilars without price reductions as of 1 December 2019 or later, subject to possible changes (German and French).
Lists of pharmaceuticals without price reductions resulting from the review in 2019
XLSX148.51 kB29 October 2020
Lists of the originals, generics, co-marketing and biosimilars with price reductions as of 1 December 2018 or later, subject to possible changes (German and French).
Lists of pharmaceuticals with price reductions resulting from the review in 2018
XLSX293.09 kB21 August 2019
Lists of the originals, generics, co-marketing and biosimilars without price reductions as of 1 December 2018 or later, subject to possible changes (German and French).
Lists of pharmaceuticals without price reductions resulting from the review in 2018
XLSX213.98 kB21 August 2019
Lists of the originals, generics, co-marketing and biosimilars with price reductions as of 1 December 2017 or later, subject to possible changes (German and French).
Lists of pharmaceuticals with price reductions resulting from the review in 2017
XLSX247.08 kB1 November 2018
Lists of the originals, generics, co-marketing and biosimilars without price reductions as of 1 December 2017 or later, subject to possible changes (German and French).
Lists of pharmaceuticals without price reductions resulting from the review in 2017
XLSX140.39 kB1 November 2018

Notifications from the FOPH on the triennial review of inclusion requirements for pharmaceuticals

Federal Office of Public Health FOPH

Health and Accident Insurance Directorate
Review of pharmaceuticals Section
Schwarzenburgstrasse 157
Switzerland - 3003 Bern

Show location on map

Triennial review of pharmaceuticals

Division of medicines

Group A

Group B

Group C

Review 2026

Information letter dated 8 December 2025 concerning the triennial review of listing requirements in 2026 / Adjustments to FOPH practice (in German and French)

List of pharmaceuticals to be reviewed in 2026 (in German and French)

Review 2025

Lists of pharmaceuticals with price reductions resulting from the review in 2025

Lists of pharmaceuticals without price reductions resulting from the review in 2025

List of pharmaceuticals subject to appeal

Previous reviews

Review 2024

Lists of pharmaceuticals with price reductions resulting from the review in 2024

Lists of pharmaceuticals without price reductions resulting from the review in 2024

Triennial review of listing requirements in 2024: Publication of the basis for assessment

Review 2023

Lists of pharmaceuticals with price reductions resulting from the review in 2023

Lists of pharmaceuticals without price reductions resulting from the review in 2023

Review 2022

Lists of pharmaceuticals with price reductions resulting from the review in 2022

Lists of pharmaceuticals without price reductions resulting from the review in 2022

Review 2021

Lists of pharmaceuticals with price reductions resulting from the review in 2021

Lists of pharmaceuticals without price reductions resulting from the review in 2021

Review 2020

Lists of pharmaceuticals with price reductions resulting from the review in 2020

Lists of pharmaceuticals without price reductions resulting from the review in 2020

Review 2019

Lists of pharmaceuticals with price reductions resulting from the review in 2019

Lists of pharmaceuticals without price reductions resulting from the review in 2019

Review 2018

Lists of pharmaceuticals with price reductions resulting from the review in 2018

Lists of pharmaceuticals without price reductions resulting from the review in 2018

Review 2017

Lists of pharmaceuticals with price reductions resulting from the review in 2017

Lists of pharmaceuticals without price reductions resulting from the review in 2017

Notifications from the FOPH on the triennial review of inclusion requirements for pharmaceuticals

Information letter dated 6 December 2024 concerning the triennial review of listing requirements in 2025

List of pharmaceuticals to be reviewed in 2025 (in German and French)

Information letter from the FOPH dated 14 june 2024 concerning the publication process for the triennial review of listing requirements in 2024 (in German and French)

Information letter dated 6 December 2023 concerning the amendments to Ordinances effective from 1 January 2024 and the triennial review of listing requirements in 2024

List of pharmaceuticals to be reviewed in 2024 (in German and French)

Information letter dated 9 December 2022 concerning the triennial review of listing requirements in 2023

List of pharmaceuticals to be reviewed in 2023 (in German and French)

List of pharmaceuticals to be reviewed in 2022 (in German and French)

Information letter dated 4 December 2020 concerning the three-year review of pharmaceuticals in 2021 / Implementation of HTA reports on pharmaceuticals

List of pharmaceuticals to be reviewed in 2021

Information letter dated 2 December 2019 concerning the three-year review of pharmaceuticals in 2020

List of pharmaceuticals to be reviewed in 2020

Information letter dated 6 December 2018 concerning the three-year review of pharmaceuticals in 2019

List of pharmaceuticals to be reviewed in 2019 (State 01.03.2019, in German and French)

Information letter dated 22 June 2018 concerning the triennal review 2018 priorities set to ensure timely implementation and differentiated cost shares for drugs and medicinal products in 2018

Information letter concerning the three-year review of drugs in 2018 (in German)

List of drugs to be reviewed in 2018 (in German)

Information letter dated 28 August 2017 concerning the implementation of the differentiated cost share and supplementary information concerning the implementation of the inclusion requirements every three years in 2017 (in German and French)

Information letter concerning the three-year review of drugs in 2017 (in German, French and Italian)

List of drugs to be reviewed in 2017 (in German)

Information letter cancelling the review of the inclusion requirements every three years 2016 (in German and French)

Index

Federal Office of Public Health FOPH